Appointed
Michelle Cervantes Vivanco
Chief Financial Officer
GCAN ·
Greater Cannabis Company, Inc.
Michelle Cervantes Vivanco as the Company’s Chief Financial Officer
Ready 8-Ks
15
Latest filing
July 31, 2026, 2:18 PM ET
Top materiality
0.90
Event mix
other_material ×8 · leadership ×3 · other ×2
Sentiment
1 pos · 3 neg · 11 neu
Executive change
recent →
Recent 8-K filings for GCAN
Highest-materiality recent filing
Trafalgar Asset Management acquires voting control of Greater Cannabis Company, appoints new CEO
- Trafalgar Asset Management purchased 100% of Series A and Series B preferred stock, gaining 96.62% voting power as of June 29, 2026.
- Porfirio Sanchez Talavera appointed CEO and Chairman; Aitan Zacharin resigned as officer and will leave board after 10-day Rule 14f-1 period.
-
Carlos Septién appointed COO and director, Michelle Cervantes Vivanco CFO and director, Ernesto Gómez Berjón CGO and director, effective after 10-day notice period.
-
Trafalgar Asset Management acquires voting control of Greater Cannabis Company, appoints new CEO
Trafalgar Asset Management purchased 100% of Series A and Series B preferred stock, gaining 96.62% voting power as of June 29, 2026.
-
GCAN files Series B Preferred Stock giving CEO Aitan Zacharin 51% voting control
Created 1,000 Series B Convertible Preferred Shares with 51% total voting power.
-
Greater Cannabis implements 1-for-1,500 reverse stock split effective Oct 15, 2025
Outstanding shares reduced from 1,349,888,436 to approximately 900,256.
-
GCAN issues 100M shares to CEO for $10K deferred salary
CEO Aitan Zacharin received 100,000,000 restricted shares on April 3, 2025.
-
GCAN replaces independent auditor Fruci with Olayinka Oyebola & Co effective Jan 25, 2023
Ended engagement of Fruci & Associates II, PLLC as independent auditor on January 25, 2023, approved by board.
-
GCAN extends note maturities to April 2023, obtains default waiver from FFG
Extended maturity of two Convertible Promissory Notes (each $272,500 principal) to April 30, 2023.
-
Licensing covers novel cannabinoid therapeutic for autism, schizophrenia, Parkinson's, Alzheimer's, and other neuropsychiatric disorders.
Executive changes
Appointed
Carlos Septién
Chief Operating Officer
GCAN ·
Greater Cannabis Company, Inc.
the Board appointed Carlos Septién as the Company’s Chief Operating Officer
Appointed
Ernesto Gómez Berjón
Chief Growth Officer
GCAN ·
Greater Cannabis Company, Inc.
Ernesto Gómez Berjón as the Company’s Chief Growth Officer
Departed
Aitan Zacharin
President, Chief Executive Officer, Treasurer
GCAN ·
Greater Cannabis Company, Inc.
Aitan Zacharin resigned from all officer positions effective immediately upon such appointment and agreed to remain as a member of the Board of Directors solely until the expiration of the ten (10) day period required under Rule 14f-1.
Appointed
Porfirio Sanchez Talavera
Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors
GCAN ·
Greater Cannabis Company, Inc.
On June 29, 2026, Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors of the Company.
Departed
Aitan Zacharin
Director
GCAN ·
Greater Cannabis Company, Inc.
Upon expiration of such period, Mr. Zacharin’s resignation as a director will become effective and Mr. Sanchez Talavera will remain as the sole director of the Company.
Departed
Mark Radom
general counsel
GCAN ·
Greater Cannabis Company, Inc.
Effective immediately after the filing of this report, Mark Radom resigned from his position of general counsel of the Company.
Departed
David Tavor
director
GCAN ·
Greater Cannabis Company, Inc.
Effective August 19, 2021, David Tavor resigned as a director of the Company.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material